[go: up one dir, main page]

BRPI0507165A - derivados de uréia - Google Patents

derivados de uréia

Info

Publication number
BRPI0507165A
BRPI0507165A BRPI0507165-8A BRPI0507165A BRPI0507165A BR PI0507165 A BRPI0507165 A BR PI0507165A BR PI0507165 A BRPI0507165 A BR PI0507165A BR PI0507165 A BRPI0507165 A BR PI0507165A
Authority
BR
Brazil
Prior art keywords
urea derivatives
xyde
prophylaxis
tumors
inhibitors
Prior art date
Application number
BRPI0507165-8A
Other languages
English (en)
Inventor
Werner Mederski
Christos Tsaklakidis
Dieter Dorsch
Bertram Cezanne
Johannes Gleitz
Original Assignee
Merck Patent Ges Mit Berschron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Berschron filed Critical Merck Patent Ges Mit Berschron
Publication of BRPI0507165A publication Critical patent/BRPI0507165A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADOS DE URéIA". A presente invenção refere-se a compostos da fórmula (I), onde X-Y-D-E, R¬ 1¬, R¬ 2¬ e R¬ 3¬ têm os significados indicados na reivindicação 1, que são inibidores do fator de coagulação Xa e podem ser empregados para a profilaxia e/ou terapia de doenças tromboembólicas e para o tratamento de tumores.
BRPI0507165-8A 2004-01-30 2005-01-07 derivados de uréia BRPI0507165A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004004731A DE102004004731A1 (de) 2004-01-30 2004-01-30 Harnstoffderivate
PCT/EP2005/000083 WO2005073201A1 (de) 2004-01-30 2005-01-07 Harnstoffderivate

Publications (1)

Publication Number Publication Date
BRPI0507165A true BRPI0507165A (pt) 2007-06-26

Family

ID=34801285

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507165-8A BRPI0507165A (pt) 2004-01-30 2005-01-07 derivados de uréia

Country Status (12)

Country Link
US (1) US20070161623A1 (pt)
EP (1) EP1709017A1 (pt)
JP (1) JP2007519645A (pt)
KR (1) KR20060128984A (pt)
CN (1) CN1914184A (pt)
AR (1) AR047514A1 (pt)
AU (1) AU2005209362A1 (pt)
BR (1) BRPI0507165A (pt)
CA (1) CA2554911A1 (pt)
DE (1) DE102004004731A1 (pt)
WO (1) WO2005073201A1 (pt)
ZA (1) ZA200607219B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
EP2373634B1 (en) 2008-12-05 2015-11-11 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
KR20120055608A (ko) * 2009-08-06 2012-05-31 메르크 파텐트 게엠베하 신규한 이환 우레아 화합물
AU2010286933A1 (en) * 2009-08-31 2012-03-15 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10113402A1 (de) * 2001-03-20 2002-09-26 Merck Patent Gmbh Biurethanderivate
DE10220048A1 (de) * 2002-05-04 2003-11-13 Merck Patent Gmbh Semicarbazidderivate
DE10302500A1 (de) * 2003-01-23 2004-07-29 Merck Patent Gmbh Carbonsäureamidderivate
DE10329457A1 (de) * 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
DE10325962A1 (de) * 2003-06-07 2004-12-23 Merck Patent Gmbh Aroylsemicarbazidderivate
DE502004001289D1 (de) * 2003-06-18 2006-10-05 Merck Patent Gmbh PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN

Also Published As

Publication number Publication date
WO2005073201A1 (de) 2005-08-11
CN1914184A (zh) 2007-02-14
JP2007519645A (ja) 2007-07-19
ZA200607219B (en) 2008-05-28
DE102004004731A1 (de) 2005-08-18
CA2554911A1 (en) 2005-08-11
AU2005209362A1 (en) 2005-08-11
EP1709017A1 (de) 2006-10-11
KR20060128984A (ko) 2006-12-14
AR047514A1 (es) 2006-01-25
US20070161623A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0408444A (pt) derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
BR0313634A (pt) Derivados de benzimidazol
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
BRPI0515477A (pt) derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd)
BRPI0410037A (pt) inibidores da fosfatidilinositol 3-cinase
BRPI0411466A (pt) derivados de 1-[(4-etinilfenil)]-2-[(fenil)]-pirrolidina-1,2-dicarboxami da como inibidores de fatores de coagulação xa e viia para o tratamento de trombose
BRPI0417708A (pt) derivados organofosfóricos dos indazóis e sua utilização como inibidores das proteìnas quinases
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BRPI0415760A (pt) derivados de benzimidazolila
BRPI0515483A (pt) derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
BRPI0515931A (pt) compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
BRPI0515499A (pt) derivados de piridina para a inibição de estearoil-coa-desaturase humana
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE50310516D1 (de) Fredericamycin-derivate
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
BRPI0416690A (pt) derivados de pirrol

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired